Journal of Diabetes Research

Research Article

Middle-Aged Indians with Type 2 Diabetes Are at Higher Risk of Biological Ageing with Special Reference to Serum CDKN2A

Table 4

Risk (OR) of high levels of CDKN2A in different study groups.


Senescence marker CDKN2A (ng/mL)	OR (95% CI) ( value)
Senescence marker CDKN2A (ng/mL)	G2 controls (reference: G1 controls)	G1 T2DM patients (reference: G1 controls)	G2 T2DM patients (reference: G2 controls)

Unadjusted	2.829	3.484	5.000
	(1.003-7.977)	(1.246-9.747)	(1.914-13.061)
	(0.049)	(0.017)	(0.001)

Model 1	3.648	3.329	5.654
	(1.190-11.183)	(1.121-9.880)	(1.873-17.064)
	(0.024)	(0.030)	(0.002)

Model 2	3.812	3.683	8.754
	(1.251-11.620)	(0.996-13.627)	(2.520-30.405)
	(0.019)	(0.051)	(0.001)

Model 3	3.221	3.212	4.356
	(1.036-10.013)	(0.898-11.493)	(1.374-13.811)
	(0.043)	(0.073)	(0.012)

Model 4	4.322	3.258	7.480
	(1.273-14.681)	(0.662-16.042)	(1.744-32.087)
	(0.019)	(0.146)	(0.007)

OR: odds ratio; CI: confidence interval; G1: 31-40 years; G2: 41-50 years; model 1: adjusted for BMI, WC, and WHR; model 2: adjusted for MDA and oxLDL; model 3: adjusted for IL-6, IL-1β, TNF-α, and MCP-1; model 4: adjusted for MDA, oxLDL, IL-6, IL-1β, TNF-α, and MCP-1; BMI: body mass index; WC: waist circumference; WHR: waist-hip ratio; MDA: malondialdehyde; oxLDL: oxidized LDL; IL-6: interleukin-6; IL-1β: interleukin- 1β; TNF-α: tumor necrosis factor α; MCP-1: monocyte chemoattractant protein-1; CDKN2A: cyclin-dependent kinase inhibitor 2A.